Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub
505(b)(2) Hybrid Risperidone Long-Acting Injectable Given Name Uzedy
Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.
You may also be interested in...
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
Following positive trial results, Teva says it is exploring options with the US FDA for filing a long-acting subcutaneous injectable version of risperidone that it is developing with MedinCell.
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.